SIGN IN
|
SIGN UP
ISSN 0973 - 9289
HOME
(current)
TOPICS
ASK A DOCTOR
GRAND ROUNDS
Question of the week
BLOGS
SUBMIT
CONFERENCE
VIDEOS
GRAND ROUNDS
Neonatal ARV prophylaxis
Reepa Agrawal
DCH, MRCPH (U.K.)
A 32 years old HIV infected pregnant female (G2P2L1) presented at 36 weeks of pregnancy for deciding neonatal antiretroviral (ARV) prophylaxis. Her HIV viral load at 34 weeks of gestation was undetectable and she was on antiretroviral therapy (ART) consisting of tenofovir, lamivudine and dolutegravir. She has opted for an elective caesarean section delivery. She had previously been on nevirapine based regimen but had developed a rash due to same and so nevirapine was omitted from her ART regimen. Her first born child was given Nevirapine (NVP) for 6 weeks as ARV prophylaxis and replacement feeding. He was HIV uninfected on testing.
What should be the neonatal ARV prophylaxis for the coming newborn baby and why?
See Previous Grand Rounds
HIV GRAND ROUNDS
A 32 years old HIV infected pregnant female (G2P2L1) presented at 36 weeks of pregnancy for deciding neonatal antiretroviral (ARV) prophylaxis. Her HIV viral load at 34 weeks of gestation was undetectable and she was on antiretroviral therapy (ART) consisting ....
HIV IN CHILDREN APPS